| Trial Title | Who can participate? | Where is the trial open? | What question is the trial asking? | Full trial information |
|---|---|---|---|---|
CTRIAL 24-09 SIMPLIFY SABR COMET |
This study is for people whose cancer has spread from the original tumor to just a few places in the body, this is called oligometastatic or oligoprogressive disease. Participants must be suitable to receive SABR, which is a type of high-dose, very precise radiation treatment that targets small areas of cancer. Whether someon is suitable for this is decided by their doctor. To join, your main (primary) cancer must have been under control for at least 3 months, and you can have between 1 and 5 small areas of cancer that are panned to be treated with SABR. |
The trial is open in:
|
The main goal of this study is to assess whether it is just as safe to give SABR (a very precise, high-dose type of radiation therapy) in a single treatment session (single fraction) as compared with the current standard of 3-5 treatment sessions. |
|
CTRIAL 21-28 E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe |
OligoCare Cohort: This group includes people with breast, prostate, bowel (colorectal), or lung cancer that has spread to a small number of places (usually up to 5). They are being treated with high-precision radiotherapy aimed at curing the cancer. ReCare Cohort: This group includes people who are receiving another course of high-dose radiotherapy to an area that has already been treated with radiation before, as part of their usual (standard) medical care |
The trial is open in:
|
The study aims to understand how radiotherapy is delivered in real-world settings, who receives it, what the short- and long-term outcomes are, and how treatment safety and effectiveness can be improved for future patients. It is an observational study, which means your treatment will not change in any way. The hospital will simply collect information about your care, and you may be asked to fill out questionnaires about how your cancer treatment affects your quality of life. |
|
CTRIAL 20-03 Spine SABR: Dose-escalated Stereotactic Ablative Body Radiotherapy (SABR) for Solid Tumour Spine Metastases |
Adults (18+) with a spinal tumour that has spread from another part of the body (oligometastatic or oligoprogressive cancer), who are suitable to receive SABR treatment. Your medical team will inform you whether you are a suitable candidate for SABR treatment. |
The trial is open in:
|
The study aims to find the highest safe SABR radiation dose that can effectively treat spinal tumours while protecting the spinal cord and surrounding organs. SABR is a special type of precise, high-dose radiation treatment and this treatment will be delivered in two hospital visits. Once the maximum safe dose is identified, 88 patients will be treated at that level to confirm safety and effectiveness. |
